These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 9151380)

  • 21. Generation of human lymphokine-activated killer cells following brief exposure to high dose interleukin 2.
    Horton SA; Oldham RK; Yannelli JR
    Cancer Res; 1990 Mar; 50(6):1686-92. PubMed ID: 2306722
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of lymphokine-activated killer activity during HIV infection: role of HIV-1 gp41 synthetic peptides.
    Cauda R; Tumbarello M; Ortona L; Kennedy RC; Shuler KR; Chanh TC; Kanda P
    Nat Immun Cell Growth Regul; 1990; 9(6):366-75. PubMed ID: 2087245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulation of in vitro porcine natural killer cell activity by recombinant interleukin-1 alpha, interleukin-2 and interleukin-4.
    Knoblock KF; Canning PC
    Immunology; 1992 Jun; 76(2):299-304. PubMed ID: 1634252
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IL-12 and IL-2 potentiate the in vitro tumor-specific activity of peripheral blood cells from cervical cancer patients.
    Verma V; Sharma V; Shrivastava SK; Nadkarni JJ
    J Exp Clin Cancer Res; 2000 Sep; 19(3):367-74. PubMed ID: 11144531
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Generation of human lymphokine-activated killer cells following an IL-2 pulse in elderly cancer patients.
    Provinciali M; Di Stefano G; Stronati S; Fabris N
    Cytokine; 1998 Feb; 10(2):132-9. PubMed ID: 9512903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sera from patients with the acquired immunodeficiency syndrome inhibit production of interleukin-2 by normal lymphocytes.
    Siegel JP; Djeu JY; Stocks NI; Masur H; Gelmann EP; Quinnan GV
    J Clin Invest; 1985 Jun; 75(6):1957-64. PubMed ID: 2989337
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Natural killer cell immunodeficiency in HIV disease is manifest by profoundly decreased numbers of CD16+CD56+ cells and expansion of a population of CD16dimCD56- cells with low lytic activity.
    Hu PF; Hultin LE; Hultin P; Hausner MA; Hirji K; Jewett A; Bonavida B; Detels R; Giorgi JV
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Nov; 10(3):331-40. PubMed ID: 7552495
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interleukin-10-secreting CD4 cells from aged patients with AIDS decrease in-vitro HIV replication and tumour necrosis factor alpha production.
    Andrade RM; Lima PG; Filho RG; Hygino J; Milczanowski SF; Andrade AF; Lauria C; Brindeiro R; Tanuri A; Bento CA
    AIDS; 2007 Aug; 21(13):1763-70. PubMed ID: 17690575
    [TBL] [Abstract][Full Text] [Related]  

  • 29. T cells and monocytes regulate the generation and functional activity of natural killer-derived lymphokine-activated killer cells.
    Atzpodien J; Gulati SC
    Stem Cells; 1993 Nov; 11(6):511-8. PubMed ID: 8111310
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Natural killer and activated killer activities in chronic liver disease and hepatocellular carcinoma: evidence for a decreased lymphokine-induced activity of effector cells.
    Hirofuji H; Kakumu S; Fuji A; Ohtani Y; Murase K; Tahara H
    Clin Exp Immunol; 1987 May; 68(2):348-56. PubMed ID: 2820634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interleukin-12 (IL-12) augments cytolytic activity of natural killer cells toward Mycobacterium tuberculosis-infected human monocytes.
    Denis M
    Cell Immunol; 1994 Jul; 156(2):529-36. PubMed ID: 7913000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Human LAK cell induction and its biological characteristics].
    Wu YY
    Zhonghua Zhong Liu Za Zhi; 1990 Jul; 12(4):254-7. PubMed ID: 2125554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lymphokine-activated and natural killer cell activity in human intestinal mucosa.
    Hogan PG; Hapel AJ; Doe WF
    J Immunol; 1985 Sep; 135(3):1731-8. PubMed ID: 3926882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of bone marrow transplantation and polyinosinic-polycytidylic acid (poly I:C) on the rescue of animals from busulfan-induced NK suppression.
    Bhoopalam N; Fried W; Benson D; Barone-Verales J; Price K
    Exp Hematol; 1989 May; 17(4):357-63. PubMed ID: 2651135
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased NKG2A found in cytotoxic natural killer subset in HIV-1 patients with advanced clinical status.
    Zhang R; Xu J; Hong K; Yuan L; Peng H; Tang H; Ma P; Zhang Y; Xing H; Ruan Y; Shao Y
    AIDS; 2007 Dec; 21 Suppl 8():S9-17. PubMed ID: 18172398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Priming with IFN-gamma restores deficient IL-12 production by peripheral blood mononuclear cells from HIV-seropositive donors.
    Harrison TS; Levitz SM
    J Immunol; 1997 Jan; 158(1):459-63. PubMed ID: 8977223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
    Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
    Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Different patterns of some systemic immunological cell markers in HIV only, and HIV/hepatitis C-infected children.
    Voiculescu CL; Bălăşoiu M; Turculeanu A; Radu C; Avramescu C; Radu E
    Pediatr AIDS HIV Infect; 1996 Feb; 7(1):31-6. PubMed ID: 11361470
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diminution of inducible lymphokine-activated killer cell activity in individuals with AIDS-related disorders.
    Gryllis C; Wainberg MA; Gornitsky M; Brenner B
    AIDS; 1990 Dec; 4(12):1205-12. PubMed ID: 2088399
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.